NCT07288359

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-12-29Est. Completion: 2031-05-09

Enrollment target: 205 participants

Locations

Tennessee Oncology PLLC, Nashville, Tennessee, United States
Novartis Investigative Site, Odense C, Denmark
Novartis Investigative Site, Jena, Thuringia, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Milan, Italy
Novartis Investigative Site, Kyoto, Japan
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Taipei, Taiwan

Contact

Novartis Pharmaceuticalsnovartis.email@novartis.com 1-888-669-6682

Other microbiome trials you might be interested in

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsPhase 1Recruiting

Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast CancerGastroEsophageal CancerBladder Cancer

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to a…

Newport Beach, United StatesEst. completion Aug 31, 2026

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.